Evaluation of the Alfred AST® system for rapid antimicrobial susceptibility testing directly from positive blood cultures

Sánchez‐Carrillo, Carlos; Pescador, Paula; Ricote, Rosa; Fuentes, Julia; Losada, Carmen; Candela, Ana; Cercenado, Emilia

doi:10.1007/s10096-019-03595-y

Cited by 17 publications

(6 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In routine clinical microbiology settings, the time to measure antibiograms from an automated or manual system ranges from 6 to 12 hours. In some cases, for example, with the use of Accelerate or by the use of the Alfred 60AST (Alifax, Nimis, IT) [16] culture system, results can be observed in a shorter time. Of note, this "laboratory time" is added to the period (usually, one night) used to isolate a microbe from a biological sample.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of bacterial proliferation with a microfluidic-based device: Antibiochip

Gallo

Ruiba²,

Zanin

et al. 2020

PLoS ONE

View full text Add to dashboard Cite

The measurement of the proliferation (and the relevant inhibition of proliferation) of microbes is used in different settings, from industry to laboratory medicine. Thus, in this study, the capacity of the Antibiochip (ELTEK spa), a microfluidic-based device, to measure the amount of E. coli in certain culture conditions, was evaluated. An Antibiochip is composed of V-shaped microchannels, and the amount of microparticles (such as microbes) is measured by the surface of the pellet after centrifugation. In the present study, different geometries, volumes and times were analyzed. When the best conditions were identified, serial dilutions of microbial cultures were tested to validate the linearity of the results. Then, with the use of wild E. coli strains isolated from medical samples, the relationship between bacterial susceptibility to antibiotics measured by standard methods and that measured by the Antibiochip was evaluated. In this report, the good quality performances of the methods, their linearity and the capacity to identify susceptible microbial strains after 60 minutes of incubation are shown. These results represent a novel approach for ultrarapid antibiograms in clinics.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of bacterial proliferation with a microfluidic-based device: Antibiochip

Gallo

Ruiba²,

Zanin

et al. 2020

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…In our study, 39 discrepant results were seen on 595 measurements (6.6%) with 8 VMDs, 18 MDs, and 13 MiDs. Other studies reported categorical agreements of 87%, 96.3%, and 97% between Alfred60 AST and routine AST with respectively Phoenix™ (BD), Vitek 2 (bioMérieux), and broth microdilution [13,14,15]. Giordana et al evaluated Alfred60 AST and compared it with another technique for direct AST testing: Pheno™ (Accelerate).…”

Section: Discussionmentioning

confidence: 99%

Performance and potential clinical impact of Alfred60AST (Alifax®) for direct antimicrobial susceptibility testing on positive blood culture bottles

Poel

Meersseman

Debaveye

et al. 2019

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

show abstract

“…For AST of GNB, an agreement of 91% with broth microdilution method results has been registered [18]. In a study of 115 BSI episodes (of which 51 and eight were caused by Enterobacterales and non-fermenting GNB, respectively), time to AST was 5 hr for the ALFRED60 system vs. 48 hr for standard microdilution method [19]. Further development (inclusion of more antibiotics active against MDR-GNB in the AST panel) and clinical studies are warranted.…”

Section: Light Scattering Technologymentioning

confidence: 94%

Rapid microbiological tests for bloodstream infections due to multidrug resistant Gram-negative bacteria: therapeutic implications

Giacobbe

Giani

Bassetti

et al. 2020

Clinical Microbiology and Infection

View full text Add to dashboard Cite

Background: Treating severe infections due to multidrug-resistant Gram-negative bacteria (MDR-GNB) is one of the most important challenges for clinicians worldwide, partly because resistance may remain unrecognized until identification of the causative agent and/or antimicrobial susceptibility testing (AST). Recently, some novel rapid test for identification and/or AST of MDR-GNB from positive blood cultures or the blood of patients with bloodstream infections (BSIs) have become available. Objectives: The objective of this narrative review is to discuss the advantages and limitations of different rapid tests for identification and/or AST of MDR-GNB from positive blood cultures or the blood of patients with BSI, as well as the available evidence on their possible role to improve therapeutic decisions and antimicrobial stewardship. Sources: Inductive PubMed search for publications relevant to the topic. Content: The present review is structured in the following way: (a) rapid tests on positive blood cultures; (b) rapid tests directly on whole blood; (c) therapeutic implications. Implications: Novel molecular and phenotypic rapid tests for identification and AST show the potential for favourably influencing patients' outcomes and results of antimicrobial stewardship interventions by reducing both the time to effective treatment and the misuse of antibiotics, although the interpretation about their impact on actual therapeutic decisions and patients' outcomes is still complex. Factors such as feasibility and personnel availability, as well as the detailed knowledge of the local microbiological epidemiology, need to be considered very carefully when implementing novel rapid tests in laboratory workflows and algorithms. Providing high-level, comparable evidence on the clinical impact of rapid identification and AST is becoming of paramount importance for MDR-GNB infections, since in the near future rapid identification of specific resistance mechanisms could be crucial for guiding rapid, effective, and targeted therapy against specific resistance mechanisms.

show abstract

Evaluation of the Alfred AST® system for rapid antimicrobial susceptibility testing directly from positive blood cultures

Cited by 17 publications

References 13 publications

Evaluation of bacterial proliferation with a microfluidic-based device: Antibiochip

Evaluation of bacterial proliferation with a microfluidic-based device: Antibiochip

Performance and potential clinical impact of Alfred60AST (Alifax®) for direct antimicrobial susceptibility testing on positive blood culture bottles

Rapid microbiological tests for bloodstream infections due to multidrug resistant Gram-negative bacteria: therapeutic implications

Contact Info

Product

Resources

About